These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3919448)

  • 21. Mexiletine and quinidine in combination in an ischemic model: supra-additive antiarrhythmic and electrophysiologic actions.
    Duff HJ; Gault NJ
    J Cardiovasc Pharmacol; 1986; 8(4):847-57. PubMed ID: 2427828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine.
    Lin JC; Quasny HA
    Pharmacotherapy; 1997; 17(3):626-30. PubMed ID: 9165570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous mexiletine in management of lidocaine-resistant ventricular tachycardia.
    Santinelli V; Chiariello M; Stanislao M; Condorelli M
    Am Heart J; 1983 Apr; 105(4):680-5. PubMed ID: 6837421
    [No Abstract]   [Full Text] [Related]  

  • 24. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
    Makkar RR; Fromm BS; Steinman RT; Meissner MD; Lehmann MH
    JAMA; 1993 Dec; 270(21):2590-7. PubMed ID: 8230644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mexiletine for control of drug-resistant ventricular tachycardia: clinical and electrophysiologic results in 44 patients.
    Waspe LE; Waxman HL; Buxton AE; Josephson ME
    Am J Cardiol; 1983 Apr; 51(7):1175-81. PubMed ID: 6340451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mexiletine in the treatment of resistant ventricular arrhythmias: enhancement of efficacy and reduction of dose-related side effects by combination with quinidine.
    Duff HJ; Roden D; Primm RK; Oates JA; Woosley RL
    Circulation; 1983 May; 67(5):1124-8. PubMed ID: 6831673
    [No Abstract]   [Full Text] [Related]  

  • 27. Quinidine syncope: torsade de pointes with low quinidine plasma concentrations.
    Jenzer HR; Hagemeijer F
    Eur J Cardiol; 1976 Dec; 4(4):447-51. PubMed ID: 63370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mexiletine for refractory-ventricular arrhythmias: results using serial electrophysiologic testing.
    DiMarco JP; Garan H; Ruskin JN
    Am J Cardiol; 1981 Jan; 47(1):131-8. PubMed ID: 7457398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical electrophysiological evaluation of mexiletine].
    Molina L; Colín L; Micheletti T; Blank S; Camacho J
    Arch Inst Cardiol Mex; 1986; 56(3):219-23. PubMed ID: 2944491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Torsade de pointes ventricular tachycardia. A complication of disopyramide shared with quinidine.
    Wald RW; Waxman MB; Colman JM
    J Electrocardiol; 1981 Jul; 14(3):301-7. PubMed ID: 7264507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias].
    Rolli A; Bonatti V; Finardi A; Favaro L; Botti G
    G Ital Cardiol; 1981; 11(4):468-76. PubMed ID: 6169578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Magnesium therapy for torsades de pointes.
    Tzivoni D; Keren A; Cohen AM; Loebel H; Zahavi I; Chenzbraun A; Stern S
    Am J Cardiol; 1984 Feb; 53(4):528-30. PubMed ID: 6695782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quinidine for ventricular arrhythmias: value of electrophysiologic testing.
    DiMarco JP; Garan H; Ruskin JN
    Am J Cardiol; 1983 Jan; 51(1):90-5. PubMed ID: 6849270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative efficacy and safety of oral mexiletine and quinidine in benign or potentially lethal ventricular arrhythmias.
    Morganroth J
    Am J Cardiol; 1987 Dec; 60(16):1276-81. PubMed ID: 3318368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epicardial activation patterns of torsade de pointes in canine hearts with quinidine-induced long QT interval but without myocardial infarction.
    Inoue H; Murakawa Y; Toda I; Nozaki A; Matsuo H; Mashima S; Sugimoto T
    Am Heart J; 1986 Jun; 111(6):1080-7. PubMed ID: 3716981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Three cases of torsades de pointes due to anti-arrhythmic agents].
    Yasuda M; Toda I; Akioka K; Teragaki M; Oku H; Takeuchi K; Takeda T; Inoue E; Ikuno Y; Horiguchi T
    Nihon Naika Gakkai Zasshi; 1986 Sep; 75(9):1262-6. PubMed ID: 3794468
    [No Abstract]   [Full Text] [Related]  

  • 37. Quinidine-induced torsade de pointes suppressed by paroxysmal atrial fibrillation.
    Maisuls E; Lorber A
    Int J Cardiol; 1987 Sep; 16(3):315-7. PubMed ID: 3654030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discordance between ambulatory monitoring and programmed stimulation in assessing efficacy of mexiletine in patients with ventricular tachycardia.
    Kim SG; Seiden SW; Matos JA; Waspe LE; Fisher JD
    Am Heart J; 1986 Jul; 112(1):14-9. PubMed ID: 3728269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparison of mexiletine and dihydroquinidine in the treatment of ventricular asystolic arrhythmia].
    Accettura D; De Toma L; Lagioia R; Mastropasqua F; Mangini SG; Scrutinio D; Rizzon P
    Cardiologia; 1985 Feb; 30(2):107-12. PubMed ID: 2415255
    [No Abstract]   [Full Text] [Related]  

  • 40. Lack of effectiveness of oral mexiletine in patients with drug-refractory paroxysmal sustained ventricular tachycardia. A study utilizing programmed stimulation.
    Palileo EV; Welch W; Hoff J; Strasberg B; Bauernfeind RA; Swiryn S; Coelho A; Rosen KM
    Am J Cardiol; 1982 Nov; 50(5):1075-81. PubMed ID: 7137034
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.